

In-vitro in-vivo correlation (IVIVC) of inhaled products using Twin Stage Impinger

Yuosef. Al ayoub ^a, Asma Buzgeia^b, Ghadeer Almousawi^b, Hassan Raza Ali Mazhar^c, B Alzouebi^d K. H. Assi^{b*},

^aEurofins Professional Scientific Services UK Limited, Unit G1 Valiant Way, I54 Business Park, Wolverhampton, WV9 5GB, UK

^bSchool of Pharmacy and Medical Sciences, University of Bradford, Bradford

^cMylan Teoranta, Inverin, Co. Galway, Ireland

^dWarwick Medical School, University of Warwick, Coventry, UK

* Corresponding author:

Email: khaassi@bradford.ac.uk

Tel: 01274234703

Abstract

In vitro dissolution testing as a form of quality control has become a necessity in the pharmaceutical industry. As such, the need to establish a method that investigates the in vitro dissolution profile of inhaled products should be taken into account. The prime focus in this study was to examine the in-vitro in-vivo correlation utilising a modified version of the Twin Stage Impinger and to promote an in vitro dissolution model by enhancing the Fine Particle Dose (FPD) collection method for dry powder inhalers.

The Twin Impinger was modified by inserting a stainless steel membrane holder disk in the base of the lower chamber. The design, with optimum drug deposition, was adopted for the dissolution study of budesonide and salbutamol. Afterwards, the membrane holder system was placed in the bottom of the dissolution vessel. Phosphate buffer saline (PBS), simulated lung fluid (SLF, Gamble solution) and Phosphate buffer (PB) were used in the study. The paddle dissolution apparatus, containing 300 mL of the medium, was operated at 75 rpm paddle speed. Samples were collected at defined time intervals and analysed using a validated HPLC method.

The largest proportion of the budesonide dose was dissolved in PBS compared to PB and SLF. This was due to the presence of surfactant (0.2% w/v polysorbate), which enhances the wettability and the solubility of the poorly soluble drug (budesonide). The similarity factors for PBS and PB were 47.6 and 69.7, respectively, using SLF as a reference, whereas the similarity factor for salbutamol dissolution between PB and SLF was 81.3, suggesting PB is a suitable substitute. Comparison using both the predicted and actual in vivo pharmacokinetics (PK) values of the two drugs, as well as the pattern of their Concentration-Time (c-t) profiles, showed good similarity, which gave an indication of the validity of this in vitro dissolution method.

Key words: Twin Stage Impinger, dissolution, Dry Powder Inhaler, budesonide, salbutamol, In vitro-in vivo correlation (IVIVC).

1 **1. Introduction:**

2 The efficacy of aerosol therapy depends on the ability of an inhaler to deliver sufficient drug
3 of suitable-particles to appropriate sites of action in the lungs (Pauwels R, Newman S, & L.,
4 1997). This, in turn, depends on airway anatomy and physiology, which change with age and
5 disease status (Martin et al., 1988; Stocks, 1995; Wohl, 1998:) and therefore should be taken
6 into account to assess both delivery and deposition. The performance of the orally inhaled drug
7 product (OIDP) is evaluated in vitro by the total aerosolised dose delivered (TDD) to the lung
8 and the aerodynamic particle size distribution (APSD). The APSD is the Critical Quality
9 Attribute (CQA) of the OIDP and the guidance requires Quality Control (QC) to characterise
10 this parameter (Labiris and Dolovich, 2003; EMA, 2006). However, the effectiveness of
11 inhaled products relies on inhaled drug particles dissolving in the lung fluid prior to absorption
12 to produce the desired pharmacological effect (Olsson *et al.*, 2011). The dissolution is
13 considered a significant step in the action and systemic absorption of the poorly soluble inhaled
14 drugs, such as glucocorticoids (Davies *et al.*, 2003). Hence, the rate of dissolution of OIDPs
15 has gained increased interest within respiratory research and among regulatory agencies (Riley
16 *et al.*, 2012).

17 Following dissolution in the fluid layer lining of the internal lung surfaces, the soluble drug
18 diffuses and is absorbed. The dissolution rate of the drug is proportional to the drug's solubility
19 (Dokoumetzidis *et al.*, 2006). The drug solubility is dependent on the formulation, the physical
20 properties of the drug and the constituents of the dissolution media. The bronchial epithelial
21 lining fluid consists of water (96%), salt, proteins, phospholipids, mucins and the surfactant
22 (Boat and Cheng, 1980; Fischer and Widdicombe, 2006).

23

24 Several studies have investigated the in vitro dissolution method for the inhaled product. In
25 these methods, Next Generation Impactor (NGI) and Andersen Cascade Impactor (ACI) have
26 been used as tools for collecting the aerosol particles (Davies *et al.*, 2003; Son *et al.*, 2010;
27 Arora *et al.*, 2010). NGI and ACI are the apparatus described in the compendial methods
28 (United States Pharmacopeia (USP, 2009), European Pharmacopeia (EP, 2007) and British
29 Pharmacopeia (BP, 2008) for inhaled products testing. In the NGI methods (Son *et al.*, 2010;
30 Huang et al., 2018; Lin et al., 2017), the inhaled particles collected for dissolution assessment
31 are only present in a fraction (less than 5%) of the Fine Particle Dose (FPD). In the ACI
32 methods, the first method (Davies *et al.*, 2003) collected the particles from the induction port.
33 These particles, however, do not represent the respirable dose (FPD), since it does not
34 differentiate between particles delivered to the lungs and those deposited in the throat. In

1 another study (Arora, 2010), the dose collection was performed by using Andersen Cascade
2 Impactor (ACI) with a collection stainless steel plate covered with polyvinylidene difluoride
3 (PVDF) filter membranes inserted in stage four of ACI only and then, after the run was
4 completed, the filter with the deposited drug was placed on the semi-permeable polyester
5 supporting membrane on the Transwell® insert containing 1.4 ml dissolution media. In this
6 study, the collected particles for dissolution assessment also represented a very small fraction
7 of the FPD dose. Recently Tay et al., (2018) modified the ACI by removing some of the
8 intermediate stages to test the dissolution of fine particle fraction. However, changing the
9 intermediate stages within the truncated ACI affects the velocity within the modified ACI
10 which change the particle cut-offs. Besides, comparing the amount collected on
11 polytetrafluoroethylene funnel (TF) and small collection plate (sCP) using the truncated ACI
12 with FPD collected using actual ACI doesn't ensure that it represents the actual FPD. Therefore
13 a more robust validation method is required to ensure that all particles collected on TF and sCP
14 have aerodynamic diameter less than about 5 µm.

15 On the other hand, we have adopted a different approach to FPD dose collection by modifying
16 a Twin Stage Impinger (TSI). A similar approach was reported by Eedara et al 2019, where the
17 dose was collected a glass plate and then was used to study the dissolution using a custom made
18 flow perfusion cell, however they modified the pharmacopoeia method by excluding the liquid
19 from stage 2 without validating how this would affect the FPD. Also they kept the same
20 distance between stage 2 and the glass plate where we found in our study using this setting led
21 to the majority of FPD dose to be deposited on the wall of stage 2 and not on the collection
22 plate. Furthermore, Hallworth and Westmoreland reported the suitability of twin impingers for
23 the routine quality assessment of inhaled aerosols during product development. They found
24 that stage one of the twin impinger apparatus closely mimics the human oropharynx at the
25 operational flow rate of 60L/min, which makes it physiologically relevant to be adapted for
26 assessing the dissolution. The authors also found that the deposition of drug aerosol from MDI
27 in stage two closely represented lung deposition (Hallworth & Westmoreland, 1987). In our
28 presented method, the modified TMS for collecting the dose was validated against the
29 pharmacopoeia method. The TSI consists of two chambers named the upper and lower stages
30 respectively, representing the upper and lower regions of the airways. In this design, the
31 pulmonary dose is collected in the lower stage (chamber). This technique improved the
32 respirable particle dose collected for dissolution to 46% of FPD. Due to its simplicity and user-
33 friendliness, the Modified Twin Stage Impinger (MTSI) saves time and labour as compared to
34 the multistage impactors (NGI & ACI). Hence, we investigated this approach for in vitro

1 dissolution of the inhaled products. This work also examined the correlation between the in
2 vitro dissolution profile and the in vivo blood c-t profile.

3 4 **2. Method:**

5 **2.1 Dose collection**

6 **2.1.1 Modified Twin Stage Impinger (MTSI)**

7 The British Pharmacopeia method for DPI performance characterisation using TSI
8 recommends adding 7 mL and 30 mL of a solvent in the upper chamber and in the lower
9 chambers (conical flasks), respectively. In the current work, the lower chamber of TSI (stage
10 2) was modified for DPI dose collection by introducing a removable stainless steel disc
11 (5cm diameter x 2mm Thickness) into the base of the conical flask (Figure 1). The stainless
12 steel disc was sprayed with silicone and then it was attached to stage 2 after it has been left to
13 dry for 30 min. Afterward, MTSI was assembled with 7 mL of water placed in stage 1. The
14 inhaler device was attached to the inlet of the MTSI. Four consecutive doses were discharged
15 into the TSI from the inhaler at flow rate of 60 L min⁻¹ for 4 s. The MTSI was then disassembled
16 and the stainless steel disk with the collected powder on its surface was then transferred into
17 dissolution vessels. The conical flask, the upper part and the connected tube between the upper
18 and the lower stages were washed with the solvent and analysed using a 25 cm column packed
19 with 5 µm C-18 (Phenomenex®). The mobile phase was methanol/acetonitrile/ acetic acid/
20 water (50:10:1.7:28.3) and the flow rate was 1.7 ml/min and the wave length was 242 nm
21 (Feddah, 2000).

22
23 **Validation of the modified version:** The TSI and its modified version (MTSI) were tested and
24 validated in two steps to study their suitability for inhaled product characterisations. The first
25 step was carried out with the addition of 30 mL of the solvent at stage 2. In the second step, the
26 sample collection disc was placed in the lower chamber (stage 2) and no solvent added. The
27 stainless steel disc was coated with silicone for 10 minutes before the start of the run. The
28 validation was conducted by comparing the budesonide fine particle fraction (FPF) of the
29 delivered dose reaching the lower chamber from TSI and MTSI. Easyhaler (containing
30 budesonide 200 micrograms/dose; two actuations) employing flow rate (60 L/min) for 5
31 seconds was used for this study (BP, 2018).

32 33 **2.2 Dissolution study**

34 **2.2.1- Dissolution apparatus**

1 A USP apparatus 2, (Labindia[®], DS 8000) with autosampler function was used for the
2 dissolution study. The dissolution study was performed with some modification by placing
3 the membrane holder in the dissolution vessel (Son *et al.*, 2010). The membrane holder
4 consisted of the insert stainless steel disk, the polycarbonate (PC) membrane which retains the
5 drug particles and allows them to diffuse on dissolution, the securing ring and the rubber o-
6 ring which seal the disk.

7 The HPLC methods of budesonide and salbutamol determination in the dissolution samples
8 were sensitive to reproducibly quantitate their two and five actuations, respectively.

9

10 **2.2.2- Dissolution media**

11 The most commonly used dissolution media for the assessment of the in vitro solubilisation of
12 the inhalation product is SLF that contains DPPC ((Pham and Wiedmann, 2001) because of its
13 similarity to the real lung fluid. However, Son, et al (2010) reported that SLF containing DPPC
14 is not suitable to use with the polycarbonate (PC) membrane barriers because DPPC forms a
15 liposomal aggregates which have a bigger size than the pore size of the PC membrane and
16 hence their diffusion through the membrane and their wetting effect is hindered. In addition, it
17 was also reported that the surfactant gives enough wetting effect for the lipophilic drug and it
18 was hypothesized that using phosphate buffer saline (PBS) as a dissolution media with a
19 membrane barrier system would be a suitable method for the quality control of this class of
20 drugs (Son, 2010).

21

22

23 Three dissolution media, described below, were used in this work:

24 A. Phosphate buffer (PB), 0.2 M, pH 7.4: This was prepared by dissolving potassium
25 dihydrogen phosphate in distilled water and pH adjusted to 7.4 with 0.1M sodium
26 hydroxide .

27 B. Phosphate buffer saline (PBS): This was prepared similarly as PB to which polysorbate
28 80 (0.2% w/v) was added (Son et al., 2010).

29 C. Gambles solution: was prepared as described by Marques *et al.*, 2011.

30

31 **2.2.3- Dissolution procedures**

32 The dose(s) of the tested drug was collected on the stainless steel disk as described above (see
33 section 2.1). The disk was removed from the Modified Twin Stage Impinger (MTSI) and
34 covered with a pre-soaked membrane using dissolution media, and sealed by the securing O-

1 ring (Son et al., 2010). The dissolution conditions and parameters described by Son et al. (2010)
2 were followed. The sealed membrane holder was placed at the bottom of the dissolution vessel
3 which contained 500 ml of the dissolution medium equilibrated to 37°C. The minimum
4 operational volume with USP apparatus 2 is 500 ml as the hydrodynamics becomes very
5 unstable for dissolution testing below this volume (Crist GB, 2009). The paddle speed set at 75
6 rpm. It was reported by Son et al (2010) that this speed enhances the diffusion of the dissolved
7 particles of the drug from the powder bed into the media as well as it is vital to maintain the
8 consistency in the dissolution media . The autosampler was programmed to draw 5 mL of the
9 sample solution from the dissolution vessel at time intervals of 5, 15, 30, 60, 90 and 120 min.
10 and replaced with fresh medium from the reservoir. The samples were syringe filtered (0.45
11 mm) and, after discarding initial 2 mL, transferred to the HPLC vials for analysis.
12 The experiments were performed in triplicate in each dissolution medium.

13

14 **2.2.4- Dissolution profile comparison**

15 The dissolution profiles were assessed by applying model independent method by using ratio
16 test procedure and pair wise comparison such as difference (f_1) and similarity (f_2) factor (Polli
17 e al., 1997). The comparison factors simplify dissolution profile data into one number (Duan
18 et al., 2011) which should be between 0-100 (Costa et al., 2001). It is argued that a similarity
19 factor (f_2) closer to 100 suggests higher similarity, while the difference factor (f_1) approaching
20 zero indicates higher dissimilarity (Costa et al., 2001).

21 The similarity factor is calculated from Equation 1 given below (Costa et al., 2001):

22

$$23 \quad f_2 = 50 \times \log \left\{ \left[1 + \left(\frac{1}{n} \right) \sum_{t=1}^n |R - T|^2 \right]^{-0.5} \times 100 \right\}$$

24

25 Equation 1: Similarity factor (f_2)

26 Where n is the number of the dissolution samples, R and T are the mean percentage of drug
27 release for the reference and the test profile, respectively, at each time interval.

28

29 **2.2.5- Conversion of dissolution profile to plasma concentration (c-t) profile**

30 Dissolution measures the rate at which the drug could form a solution after it is released from
31 the dosage form. It is usually performed to predict the dissolution of the drug in the GI tract
32 and more recently to estimate dissolution of the drug in the airways.

1 The convolution method that was reported by Qureshi (2010) to study the IVIVC for diltiazem
2 products has been adapted in this work. The convolution method utilises the data obtained from
3 the dissolution to estimate the blood drug levels using pharmacokinetic parameters of the tested
4 product which could be obtained from the literature. The authors of the presented work assume
5 that this approach has the potential to be extrapolated for the study of IVIVC of inhaled product
6 as dissolution is the property of the product and it is unlikely to change the pharmacokinetics
7 parameters of the drug (Qureshi (2010)).

8 Qureshi (2010) described the method to transform in vitro dissolution profile to in vivo plasma
9 concentration profile. Firstly, the dissolution percentage of drug released is converted to the
10 amount of drug for each sampling time point. The amount of drug at each time point reflects
11 on the diffusion and release of the drug through the membrane of the collection disc. This
12 amount is multiplied by the bioavailability factor of the drugs to obtain the amount available
13 in the blood. Finally, the drug concentration for each time point is calculated by dividing the
14 amount in the blood by the distribution volume. Subsequently, the amount of the drug
15 eliminated from the blood is estimated using its reported elimination rate (Derendorf *et al.*,
16 1998). The total bioavailable drug is obtained by adding up all the drug amounts for each time
17 point.

18 The c-t profile is drawn by plotting the time (h) on the x-axis and the concentration (ng/L) on
19 the y-axis (Qureshi, 2010).

21 **3. Results and Discussion**

22 **3.1- Method Validation with Modified Twin Stage Impinger (MTSI)**

23 The performance of the MTSI was validated to ensure that the alteration and the absence of the
24 30 mL solvent in the lower chamber had not affected the particle deposition. The FPD of
25 budesonide was compared between TSI and MTSI using the BP (2018) method.

26
27 Figure 2 shows the mean (n=5) deposited mass of two budesonide actuations in each part of
28 TSI and MTSI. The relative standard deviation (RSD) of the mass obtained for five runs for
29 the throat, lower and upper chambers was < 0.5%.

30
31 The effect of the distance (x) between the filter and the surface of the lower chamber base
32 (inserted disk) on the collected drug amount on the inserted disk was also studied (Figure 3).
33 The several levels studied included: 0.2 cm, 1 cm, 2 cm and >2 cm (Figure 4A, 4B) using two
34 actuations of budesonide Easyhaler.

1 The results revealed that the high level at 2 cm (Figure 4) led to reduced amount collected on
2 the disk, while increasing deposition on the flask wall. Level >2 cm including 3 and 4 cm
3 resulted in even more reduction of the drug amount collected on the disk. This is because the
4 position of the filter at this distance was too far from the disk; therefore, the delivered amount
5 spread on the flask wall. On the other hand, the 0.2 cm filter height led to the highest drug
6 amount on the disk, because the position of the filter was close enough to the inserted disk
7 surface, which minimised loss of the drug particles to the flask wall. Additionally, the 0.2cm
8 filter height gives enough distance to allow twin impinger disassembling without disrupting
9 the amount of drug on the inserted disk. Therefore, based on this study the distance (x) 0.2 cm
10 was used during the dose collection.

11

12 **3.2- Dissolution study**

13 The dissolution of the drug through the membrane was measured by quantifying the amount of
14 drug diffused from the membrane on the stainless steel disc into the dissolution medium. This
15 diffusion is controlled and affected by the membrane pore size, tortuosity and thickness. The
16 polycarbonate membranes used in this study were of 6 μm uniform thickness, having uniform
17 and precise non-tortuous air-bubble free 0.05 μm pores, possessing uniform cylindrical
18 swelling-resistant channels, thereby facilitating smooth diffusion and un-restricted dissolution.
19 They do not create air bubbles and they are composed of homogenous 0.05 μm non-tortuous
20 cylindrical pores on their surface (Son *et al.*, 2009; Marre *et al.*, 2001).

21

22 **Budesonide dissolution profile**

23 The dissolution profile of budesonide (BD) was studied in three media: Gambles solution, 0.2M
24 phosphate buffer (PB) and phosphate buffer saline (PBS). The results show that a large
25 proportion of budesonide was released in these media (Figure 5, Table 1). This shows the
26 advantage of the modified Twin Impinger design as it allows for conducting the dissolution
27 study using the minimum number of doses (only 2 doses were actuated from the inhalers) and
28 hence forming a thin powder bed on the disk. This correlates with the fact that the thickness of
29 the powder on the disk has a significant effect on the powder wetting inside the membrane
30 holder and hence on the drug release, especially for the lipophilic drug (Son *et al.*, 2010),
31 Besides, the thick powder bed has more agglomerated drug particles, which leads to surface
32 area reduction, that is an important factor for the wettability and solubility of poorly soluble
33 drugs (May, 2013). The solubility of BD in SLF was previously measured using the shake-
34 flask method (Jouyban, 2010) and it was 14.74 $\mu\text{g/ml}$ while its reported solubility in PB and

1 PBS was 17 $\mu\text{g/ml}$ and 53 $\mu\text{g/ml}$ respectively (May, 2013). The dissolution curve shows that
2 the cumulative release percentage of budesonide in the PBS after 2 hours was $95.76 \pm 1.72\%$
3 and the residual drug amount on the membrane holder was 2.55 μg (Figure 5 A, Table 1). As
4 for the dissolution profile of budesonide obtained using Gambles solution, these values were
5 $80.78 \pm 3.6\%$ and 16.6 μg (Figure 5 C, Table 1). Further, the budesonide dissolution profile in
6 PB produced $78.88 \pm 3.99\%$ and 14.4 μg (Figure 5B, Table 1). In addition, it can be noticed that
7 the dissolution profiles for budesonide in SLF, PBS and PB followed similar trend of the reported
8 budesonide solubility in these media.

9
10 The similarity factor (f_2) between the phosphate buffer saline (PBS) and phosphate buffer (PB)
11 was calculated using Gambles solution (SLF) as a reference. SLF does not contain surfactant
12 and it is usually used as a model for the lung fluid (Stopford *et al.*, 2003; Colombo *et al.*, 2008).
13 The f_2 values were 47.64 and 69.74 for PBS and PB, respectively, which shows that the
14 phosphate buffer (PB) can be used as an alternative dissolution media to SLF for testing
15 budesonide dissolution. Unlike SLF, phosphate buffer saline (PBS) contains 0.2% (w/v)
16 polysorbate 80 (surfactant) which enhances drug saturation solubility and the wettability of the
17 hydrophobic drug, thereby preventing the aggregation and enhancing the dissolution rate (Riley
18 *et al.*, 2012; Wiedmann *et al.*, 2000; Son *et al.*, 2009). Figure 5 (D) shows that the PBS
19 dissolution media gave the highest dissolution profile as compared to the SLF and PB which is
20 likely due to the presence of surfactant (polysorbate 80) in the PBS composition. However, the
21 fact that PBS f_2 value is less than 50 suggests that PBS cannot be used as alternative dissolution
22 media to SLF for testing budesonide dissolution profile.

23 It is worth noting that the lowest budesonide in vitro dissolution profile was in the SLF
24 (Gambles solution). Interestingly, SLF and SLF containing dipalmitoylphosphatidylcholine
25 (DPPC) are commonly used as dissolution media for the assessment of the in vitro
26 solubilisation of the inhalation products. Nevertheless, as indicated in the literature, using SLF
27 containing DPPC with the polycarbonate membrane barriers is not practical (Son *et al.*, 2010).
28 On the other hand, PBS gives enough wetting for the lipophilic drug (budesonide) due to
29 presence of the surfactant (polysorbate 80) and its compatibility with a membrane barrier
30 system. The results of current work, therefore, indicate that PBS could be an appropriate
31 dissolution medium that can serve as a quality control test for hydrophobic drugs.

32

33 **Salbutamol dissolution profile**

1 Phosphate buffer saline (PBS) was excluded from the dissolution study for salbutamol sulphate
2 (SS) since it showed the lower similarity factor (f_2) value (47.64) compared to SLF (Gambles
3 solution) for budesonide. The cumulative release percentages after one hour for the dissolution
4 profile using PB and SLF were 81.39% and 81.26%, respectively (Table 2). This implies that
5 most of the SS delivered dose deposited on the disk dissolved in the first hour. This high
6 dissolution is due to high solubility of salbutamol sulphate which was 11.8 in SLF and 14.5
7 mg/ml in PB. The dissolution profile is heavily dependent on the solubility of the drug in the
8 dissolution medium. The higher the solubility, the faster the dissolution. Also, release profiles
9 vary depending on the dissolution pattern of the drug product in different media.

10
11 Figure 6 shows that approximately 80% of SS was released within the first 5 minutes of
12 dissolution and the rate of dissolution in the two media decreased with time. Further, the trends
13 of both profiles were similar. Additionally, the respective dissolution profiles were more
14 independent of the dissolution in the aqueous media and on drug loading and reflected the high
15 solubility of SS in water (Son *et al.*, 2010).

16
17 The similarity factor (f_2) between SLF (used as reference) and PB was 81.35. This high f_2 value
18 indicates that PB is a suitable substitute to simulate lung fluids for in vitro dissolution
19 assessment of hydrophilic drugs since it is simple and consists of fewer ingredients. Besides,
20 PB preparation is easier and faster as compared to SLF. These results are consistent with
21 budesonide dissolution profile in that the similarity factor (f_2) was 69.74 (>50) for SLF and PB.

22 **3.3 In-vitro In-vivo Correlation**

23 The c-t profile prediction has gained increasing importance in drug development and
24 pharmaceutical product evaluation (Qureshi, 2010). A dissolution profile can be
25 mathematically converted to a blood concentration-time profile (c-t profile) by convolution
26 (Sakore and Chakraborty, 2011) using the in vivo pharmacokinetic parameters reported in the
27 literature (Qureshi, 2010). The pharmacokinetic parameters include bioavailability factor,
28 volume of distribution, elimination half-life ($t_{1/2}$) and the elimination rate constant (K_e)
29 (Derendorf *et al.*, 1998). For the current work these pharmacokinetic parameters for budesonide
30 and salbutamol were respectively obtained from Derendorf *et al.* (1998) and Jiang *et al.* (2016).

31
32 Table 3 and Figures 7 and 8 show the predicted C_{max} and t_{max} measured from the predicted c-t
33 profile. The table also compares the corresponding in vivo values.

1 The comparison of the predicted c-t dissolution profiles (Figures 7 and 8) with the in vivo c-t
2 profile of the inhaled budesonide (Derendorf *et al.*, 1998) and salbutamol (Jiang *et al.*, 2016),
3 clearly show their similar release characteristics and indicate the in vivo predictive
4 effectiveness of the in vitro dissolution method.

5
6 The t_{max} values obtained from the predicted profile for both budesonide and salbutamol using
7 PB and SLF dissolution media resembled the actual in vivo values (Table 3). However, the t_{max}
8 for budesonide using the PBS dissolution medium was about one hour, which is higher than
9 the in vivo t_{max} range. This could be due the presence of the polysorbate 80 surfactant, which
10 is different from the real lung surfactant (DPPC).

11
12 Further, the C_{max} values were different and reflected the difference in the initial budesonide
13 dose used for in vivo (400 μ g) and in vitro (200 μ g) studies. In one of the clinical studies,
14 Kaiser (1999) found that C_{max} was linearly related to the budesonide dose and noted that the
15 C_{max} was increased by a factor of ~ 2 as the dose was doubled. In the present study, the in vitro
16 predicted C_{max} for the 200 μ g dose was 0.21-0.24 nmol/L. Hence, the in vitro predicted C_{max}
17 for the 400 μ g dose would be 0.42-0.48 nmol/L. The variability between predicted C_{max} values
18 from the real in vivo values may also be due to the fact that 46% of the FPD that had deposited
19 on the disk only (not all the FPD) was used for the dissolution study. However, in the real in
20 vivo plasma study, the FPD that would reach the lung might thereby lead to a higher C_{max} value.
21 Increasing the in vitro FPD collection efficiency could therefore enhance the predictive
22 effectiveness of in vitro dissolution for in vivo studies.

23 24 **4. Conclusion**

25 We have conducted the dissolution on more than 46% of the fine-particle dose (FPD). This
26 design is simple, easy and fast for testing dissolution of inhaled products. We believe that there
27 is a potential for this design to be used in quality control and for evaluating the
28 manufacturability of inhaled products by studying the in vitro/in vivo correlation (IVIVC) of
29 inhaled particles.

30 Our proposed IVIVC model is a suitable and practical procedure to obtain blood drug c-t
31 profiles from dissolution studies. The current suggested model predicted the PK parameters'
32 values fairly accurately, making the design more cost- and time-effective.

33 34 **5. References:**

- 1 Arora, D., Shah, K A., Halquist, M S., and Sakagami, M. (2010) In Vitro aqueous fluid-
2 capacity-limited dissolution testing of respirable aerosol drug particles generated from inhaler
3 products, *Pharmaceutical Research*, 27, 786-795.
- 4 Boat, T F., Cheng, P W. (1980) Biochemistry of airway mucus secretions. *Fed Proc*, 39,
5 3067–3074.
- 6 Costa, P., and Lobo, J M S.(2001) Modeling and comparison of dissolution profiles.
7 *European Journal of Pharmaceutical Sciences*, 13, 123–133.
- 8 Colombo, C., Monhemius, A. J., Plant, J. A. (2008) Platinum, palladium and rhodium release
9 from vehicle exhaust catalysts and road dust exposed to simulated lung fluids. *Ecotox.*
10 *Environ. Safe*, 71, 722–730.
- 11 G. Bryan Crist, B G. (2009) Trends in Small-Volume Dissolution Apparatus for Low-Dose
12 Compounds, *Dissolution Technologies*, 6,19-23.
- 13 Davies, M N., and Feddah, R M. (2003) A novel method for assessing dissolution of aerosol
14 inhaler products. *International Journal of Pharmaceutics*, 255 ,175–187.
- 15 Dokoumetzidis, A., and Macheras, P. (2006) A century of dissolution research: From Noyes
16 and Whitney to the Biopharmaceutics Classification System. *International Journal of*
17 *Pharmaceutics*, 321, 1-11.
- 18 Duan, J H., Riviere,K., Marroum,P. (2011) In vivo bioequivalence and in vitro similarity factor
19 (f2) for dissolution profile comparisons of extended release formulations: how and when do
20 they match?, *Pharmaceutical Research*, 28, 1144-1156.
- 21 Derendorf, H., Hochhaus. G., Meibohm, B., Möllmann, H., and Barth, J. (1998)
22 Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. *J Allergy Clin Immunol*,
23 101, S440-S446.
24
- 25 Fischer, H., and Widdicombe, J H. (2006) Mechanisms of acid and base secretion by the
26 airway epithelium. *J Membr Biol*, 211,139–150.
- 27 Hallworth, G. W., & Westmoreland, D. G. (1987). The twin impinger: a simple device for
28 assessing the delivery of drugs from metered dose pressurized aerosol inhalers. *J Pharm*
29 *Pharmacol*, 39(12), 966-972.
- 30 Huang, Z., Lin, L., McGoverin, C., Liu, H., Wang, L., Zhou,ML., Wu, C. (2018). Dry powder
31 inhaler formulations of poorly water-soluble itraconazole: A balance between in-vitro
32 dissolution and in-vivo distribution is necessary. *International Journal of Pharmaceutics* 551,
33 103-110.
- 34 Jiang B, Ruan Z, Chen J, Lou H, Shao R, Jin F and Shen H. 2016. Pharmacokinetic properties
35 and bioequivalence of orally inhaled salbutamol in healthy Chinese volunteers. *Drug*
36 *Development and Industrial Pharmacy*. 42 (9), pp: 1476-1481.
37
- 38 Jouyban A, *Handbook of Solubility Data for Pharmaceuticals*, CRC Press, Taylor and Francis
39 Group, 2010

- 1 LABIRIS, N. R. & DOLOVICH, M. B. 2003. Pulmonary Drug Delivery. Part II: The Role of
2 Inhalant Delivery Devices and Drug Formulations in Therapeutic Effectiveness of
3 Aerosolized Medications. *British Journal of Clinical Pharmacology*, 56(6), 600-612.
- 4 Lin, L., Quan, G., Peng, T., Huang, Z., Singh, V., Lu, M., Wu, C., 2017. Development of fine
5 solid-crystal suspension with enhanced solubility, stability, and aerosolization performance
6 for dry powder inhalation. *International Journal of Pharmaceutics*, 533, 84-92
- 7 Marques, M R C., Loebenberg, R. and Almukainzi, M. (2011) Simulated biological fluids
8 with possible application in dissolution testing. *dissolution technologies*.
- 9
- 10 Marre, S., Palmeri, J. (2001) Theoretical study of aerosol filtration by nucleopore filters: The
11 intermediate crossover regime of Brownian diffusion and direct interception. *J. Colloid*
12 *Interf. Sci.*, 237 (2), 230–238.
- 13
- 14 MARTIN, T. et al. Relationship between maximal expiratory flows and lung volumes in
15 growing humans. *Appl Physiol*, v. 65:822-828, 1988.
- 16
- 17 May S. (2013) Dissolution Testing of Powders for Inhalation, Ph.D. Thesis, University of
18 Saarlandes.
- 19 Pham, S., Wiedmann, T.S., (2001). Dissolution of aerosol particles of budesonide in Survanta
20 (TM), a model lung surfactant. *J. Pharm. Sci.* 90, 98–104.
- 21
- 22 Pauwels R, Newman S and L., B. (1997). Airway deposition and airway effects of antiasthma
23 drugs delivered from metered-dose inhalers. *Eur Respir J* 10: 2127-2138.
- 24 Polli, J E., Rekhi, G S., Augsburger, L L., and Shah, V P. (1997) Methods to compare
25 dissolution profiles and a rationale for wide dissolution specifications for metoprolol tartrate
26 tablets, *Journal of Pharmaceutical Sciences*, 86, 690-700.
- 27 Olsson, B., Bondesson, E., Borgström, L., Edsbäcker, S., Eirefelt, S., Ekelund, K.,
28 Gustavsson, L. and Myrbäck, T H. Pulmonary drug metabolism, clearance, and absorption.
29 Chapter 2 of (H.D.C. Smyth and A.J. Hickey (eds.) (2011) *Controlled Pulmonary Drug*
30 *Delivery*, 21 Advances in Delivery Science and Technology, DOI 10.1007/978-1-4419-9745-
31 6_2, © Controlled Release Society 2011).
- 32 Qureshi, SA. (2010) In Vitro-In Vivo Correlation (IVIVC) and Determining Drug
33 Concentrations in Blood from Dissolution Testing – A Simple and Practical Approach. *The*
34 *Open Drug Delivery Journal*, 4, 38-47.
- 35 Riley, T., Christopher, D., Arp, J., Casazza, A., Colombani, A., Cooper, A., Dey, M.,
36 Maas, J., Mitchell, J., Reiners, M., Sigari, N., Tougas, T., and Lyapustina, S. (2012)
37 Challenges with developing in vitro dissolution tests for orally inhaled products (OIPs).
38 *AAPS PharmSciTech.*, 13 (3), 978-989.
- 39 Srichana, T., Martin, G. P. and Marriott, C. (1998). Dry powder inhalers: The influence of
40 device resistance and powder formulation on drug and lactose deposition in vitro. *Eur J*
41 *Pharm Sci* 7(1): 73-80.

- 1 Stocks, J. (1995). Developmental physiology and methodology. *Am J Respir Crit Care Med*
2 151:S15-S17.
- 3 Son, Y. J., Horng, M., Copley, M. and McConville, J. T. (2010) Optimization of an in vitro
4 dissolution test method for inhalation formulations. *Dissolution Technologies*, 6-13.
- 5 Stopford, W., Turner, J., Cappellinib, D. and Brocka, T. (2003) Bioaccessibility testing of
6 cobalt compounds. *J. Environ. Monit.*, 5, 675–680.
- 7
- 8 Sakore, S., and Chakraborty, B. (2011) *In vitro–in vivo* correlation (IVIVC): A strategic tool
9 in drug development. *J Bioequiv Availab* S3. Doi: 10.4172/jbb. S3-001.
- 10
- 11 Tay, J. Y., Liew, C. L., Heng, P. W. S. (2018). Dissolution of fine particle fraction from truncated
12 Andersen cascade impactor with an enhancer cell. *International Journal of Pharmaceutics*,
13 545, 45-50
- 14
- 15 Wohl, M. (1998). Developmental physiology of the respiratory system. In: Chernick V, Boat
16 TF, Kendig EL, Editors. *Kendig's Disorders of the Respiratory Tract in Children*, 5th ed,
17 Philadelphia: Saunders 19-27.
- 18 Wiedmann, T. S., Bhatia, R., Wattenberg, L. W. (2000). Drug solubilization in lung surfactant.
19 *J. Control. Release*, 65, 43–47.
- 20
- 21 USP 2009. United States Pharmacopoeia 30-NF 25 Aerosols, nasal sprays, metered dose
22 inhalers, and dry powder inhalers., 601.
- 23 EP 2007. European Pharmacopoeia. Preparation for inhalation. 5th Edition, 2843-2847.
- 24 BP 2008. British Pharmacopoeia.

25
26
27

Figure captions

- 28 Figure 1. A schematic diagram showing MTSI (A) The modified TSI, (B) The lower chamber
29 flask fitted with the insert disk, (C) The modified flask, the inserted stainless steel disk and
30 the securing ring, (D) *Stainless steel disk with 5 actuations of the drug.
31 *The inserted stainless steel disk provides an airtight seal simply by push on at the bottom of
32 the lower chamber flask
- 33
- 34 Figure 2. Particles deposition of budesonide Easyhaler using the conventional Twin
35 Impinger (lower chamber contains 30 ml methanol) and using modified version of Twin
36 Impinger (lower chamber dry without 30 ml methanol).
37 Upper dry: modified Twin Impinger (lower chamber dry without 30 ml methanol).
38 Upper with: conventional Twin Impinger (lower chamber contains 30 ml methanol)
- 39
- 40 Figure 1. A schematic diagram of Twin Impinger lower chamber.
- 41

1 Figure 4. A comparison the amount of budesonide collected in the Twin Impinger lower
2 chamber parts (tube, flask and the inserted disk) (A) at 0.2cm and 1cm filter height. (B) at
3 0.2cm and 2cm.

4

5 Figure 5 . (A) The dissolution profile of BD in PBS. (B) The dissolution profile of BD in
6 PB.(C) dissolution profile of BD in SLF1. (D) Comparison of BD dissolution profile of three
7 dissolution media, PBS, PB and SLF.

8 All values are mean (SD), n=3

9

10 Figure 6. Comparison of the dissolution profile of SS in PB and SLF

11

12 Figure 7. The predicted C-t profiles for BD in three dissolution media (phosphate buffer (PB),
13 phosphate buffer saline (PBS) and simulating lung fluid (SLF).

14

15 Figure 8. Predicted C-t profiles derived from dissolution profiles of SS in PB and SLF

16